Vobarilizumab
Also known as: ALX-0061, anti-IL-6R Nanobody, BMS-986165, Vobarilizumab
Source Vobarilizumab at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Vobarilizumab is a humanized IgG1 monoclonal antibody targeting the IL‑6 receptor, investigated for treatment of rheumatoid arthritis and other autoimmune inflammatory diseases.
Mechanism of Action
Binds to both soluble and membrane-bound IL‑6 receptor, preventing IL‑6 mediated signaling
Routes of Administration
Goals & Uses
- Reduction of rheumatoid arthritis disease activityAnti Inflammatory / AutoimmuneModerate
- Psoriatic arthritisAutoimmune DiseaseModerate
- Suppression of IL-6 mediated inflammationImmunomodulationModerate
- Rheumatoid arthritisAutoimmune DiseaseModerate
- Reduction of systemic lupus erythematosus (SLE) disease activityAnti Inflammatory / AutoimmuneLow
Contraindications
- Known hypersensitivity to the drug or excipientsAllergyHigh
- Known hypersensitivity to vobarilizumab or Nanobody componentsImmunologicHigh
- Active serious infectionInfectionHigh
- Active serious infectionsInfectiousHigh
- Active tuberculosisInfectiousHigh
Adverse Effects
- Injection site reactionsLocalCommon
- Elevated liver enzymes (ALT/AST)HepaticUncommon
- NeutropeniaHematologicRareLow neutrophil count
- Infections (upper respiratory tract, urinary tract)InfectiousCommon
- Injection‑site reactionsLocalCommon
- Upper respiratory tract infectionsInfectious DiseaseCommon
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
- HyperlipidemiaMetabolicUncommon
Drug Interactions
- Live vaccinesHigh
- Other immunosuppressants (e.g., methotrexate, JAK inhibitors)Moderate
- CYP450 substrates with narrow therapeutic indexModerate
- Other immunosuppressants (e.g., methotrexate, azathioprine)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Patients with history of diverticulitis or GI perforationGastrointestinalRelative
- Pediatrics (<18 years)AgeRelative
- Patients with latent tuberculosisInfectious DiseaseRelative
Regulatory Status
- European UnionInvestigationalUnder clinical evaluation
- United StatesInvestigationalPhase 3 trials for RA ongoing
- United KingdomInvestigationalNot yet authorized
No regulatory approvals obtained in any jurisdiction. Phase II trials conducted in RA and SLE; Ablynx was acquired by Sanofi in 2018. Development in SLE was discontinued following Phase II results.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Vobarilizumab?
Vobarilizumab is a humanized IgG1 monoclonal antibody targeting the IL‑6 receptor, investigated for treatment of rheumatoid arthritis and other autoimmune inflammatory diseases.
What is Vobarilizumab used for?
Vobarilizumab is educationally associated with: Reduction of rheumatoid arthritis disease activity, Psoriatic arthritis, Suppression of IL-6 mediated inflammation, Rheumatoid arthritis, Reduction of systemic lupus erythematosus (SLE) disease activity. Educational only — not medical advice.
How is Vobarilizumab administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Vobarilizumab?
Reported adverse effects include: Injection site reactions, Elevated liver enzymes (ALT/AST), Neutropenia, Infections (upper respiratory tract, urinary tract), Injection‑site reactions, Upper respiratory tract infections, Elevated liver enzymes, Hyperlipidemia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Vobarilizumab?
Recorded contraindications: Known hypersensitivity to the drug or excipients, Known hypersensitivity to vobarilizumab or Nanobody components, Active serious infection, Active serious infections, Active tuberculosis. Consult a qualified clinician before use.